During this July, The House of diabetes of Sfax organized the Djerba Summer Camp 2018 in close partnership with the house of Diabetes of Djerba,
It was a great initiative by the Club of Young Diabetics of Sfax to promote healthy lifestyle for young diabetics, to share experiences and an occasion to enjoy the summer all together!
Last years’ summer camp was in the Island of Kerkennah and regrouped young diabetics from the house of diabetes from Sfax. This year’s edition is the first close collaboration between the House of Diabetes of Sfax and the House of Diabetes of Djerba.
The 14 participants are originally from Sfax and Djerba, with an age range between 15 years old and 21 years old, were involved in a set of diversified activities during the 3 days’ camp: dietetic workshops, first aid workshop and daily self-monitoring workshops. The workshops were animated by Novo Nordisk therapeutic educator with the presence of some HCPs Healthcare professionals of both House of Diabetes of Sfax and Djerba.
During this summer camp, the group of youngsters officially elected new patients experts. They will be new focal points to assist both House of Diabetes in the accompaniment of new patients. The young participants enjoyed also the sunny beaches of Djerba along with games and trips to nearby places as the flamingo island.
Novo Nordisk Tunisia has been supporting the House of Diabetes of Sfax, Djerba and Tunis for three years and encouraging the diversification of their activities to help people living with diabetes to enjoy their lives, and to offer a nurturing and safe environment for the younger ones.
Novo Nordisk Tunisia has supported the Association of Endocrinologists and Diabetologists of Sfax for more than a year. This NGO focuses its work on patients’ patients’ therapeutic education through the House of Diabetes of Sfax and through scientific seminars for Healthcare professionals.
We are honored to announce that the Association of Endocrinologists and Diabetologists of Sfax has been accepted as a full member within the International Diabetes Federation, becoming the first Tunisian NGO to join this internationally recognized federation.
Saturday, 23rd of June, was the official launch of the third House of Diabetes in Tunisia, on the southern island of Djerba in collaboration with Novo Nordisk Laboratories. The inaugural ceremony took place in the presence of esteemed guests: the Minister of Social Affairs, The Ambassador of the kingdom of Denmark in Tunisia, the Governor of Madnin district, the president of the Association of Doctors of Sfax and the vice-president of the STEDIAM (The Tunisian Society of Endocrinology). A wide range of civil society actors, activists and healthcare professionals from all sectors were also present.
Houses of Diabetes are organizational structures where people with diabetes, their families and friends can access educational sessions and materials, be heard and counselled, and gather for various social and community activities. These structures already exist in both of the biggest cities of Tunisia: Tunis and Sfax. Also supported by Novo Nordisk Tunisia, they welcome all year round people with diabetes and those who surround them and take care of them. In 2017, Novo Nordisk has sponsored more than thirty activities in the houses of diabetes of Tunis and Sfax, such as screening, awareness sessions and scientific symposia, organized by volunteers and medical societies.
The new House of Diabetes of Djerba, located in front of the bus and coach terminal, will be easily accessible to people living in the Tunisian South-East. Co-managed by the Association of people with diabetes of Djerba and the Association of doctors of Djerba, and chaperoned by the House of Diabetes of Sfax, the new House was supported by Novo Nordisk Tunisia since the early stages of its conception.
Thanks to a multi-lateral partnership, involving Novo Nordisk Tunisia, scholarly associations, non-profit organizations, and the public sector, the project was carried out effectively and within four months the House of Diabetes was inaugurated on the island. Today, thousands of people living with diabetes in the Tunisian South-East, a priority development region, will have access to educational services, nutritional counselling, and other important activities in the management of diabetes, with this new organization.
During the inaugural ceremony, the Minister of Social Affairs held a speech where he highlighted the burden of diabetes in Tunisia. He presented diabetes as a fast-growing epidemic with dramatic social and public health consequences. In fact, the prevalence of Type 2 Diabetes in Tunisia is estimated at 15%, with a higher prevalence in the urban regions in comparison to the rural regions . It is one of the fifth leading causes of death in the country and the latest figures predict that by the year 2027, about 27% of the Tunisian population will have diabetes. Furthermore, the Minister also indicated the importance of prevention, in order to contain the epidemic and its economic and social burdens.
“The burden of non-communicable diseases is, in fact, a challenge for the Tunisian health system. Moreover, many people with diabetes are unable to achieve optimal control of their health conditions. Novo Nordisk Tunisia position itself as a partner of the Ministry of Health, supporting national efforts to achieve the sustainable development goal of reducing non-communicable diseases”, declared Mohamed Larbi Jelassi Head of Market Access and Public Affairs at Novo Nordisk Tunisia during the inaugural ceremony, on Saturday.
Novo Nordisk Tunisia supports patient education in the Houses of Diabetes and supports screening campaigns in different regions of the country including hard-to-reach communities. Jelassi also explained how Novo Nordisk has a history of more than 30 years of collaboration with the country, providing insulins and other medicine even through hardship periods such as the ongoing crisis.
Her Excellency Julie Elisabeth Pruzan-Jorgensen the Ambassador of the Kingdom of Denmark in Tunisia also held a speech during the inaugural ceremony describing the “strong relations between Denmark and Tunisia” and how Novo Nordisk Tunisia falls within a partnership built on mutual respect and trust between the two countries.
This event was part of a long history of collaboration that will endure and flourish. Novo Nordisk Tunisia has framed a long-term strategy to strengthen our private-public partnership and ensure a continuous access to our products for patients all over Tunisia.
. a. S. B. A. W. A. P. T. H. A.-S. S. B. B.
M. F. D. a. N. A. Habiba Ben Romdhane, «Prevalence of diabetes in
Northern African countries: the case of Tunisia,» BMC Public
Health, pp. 14, 86, 2014.
 Institute for Health Metrics and Evaluation, University of Washington, «GBD Compare | Viz Hub,» 2016. [En ligne]. Available: https://vizhub.healthdata.org/gbd-compare/. [Accès le 21 06 2018].
 O. Saidi, M. O’Flaherty, N. Ben Mansour, W. Aissi, O. Lassoued, S. Capewel, J. A. Critchley, D. Malouche et H. Ben Romdhane, «Forecasting Tunisian type 2 diabetes prevalence to 2027: validation of a simple model,» BMC Public Health, p. 15: 104, 2015
Novo Nordisk has always aspired for Excellency and has always kept a positive footprint in its environment.
In a recent international study, the general public ranked Novo Nordisk second by its reputation among the pharmaceutical industries.
It is the annual study of the Reputation Institute: Pharma RepTrak report .
Carried out during the first two months of 2017, this study included more than 16,500 people, familiar with the pharmaceutical industry and holded within 8 countries.
Participants ranked pharmaceutical companies primarily on their reputation by taking into consideration other factors such as performance, products and services, innovation, work environment and governance.
An excellent surprise: Better than last year
The Pharma RepTrak 2017 study revealed excellent evaluations for the pharmaceutical industry in general, and Novo Nordisk in particular despite a turbulent year.
Novo Nordisk is second after the American company AbbVie. With a score of 75.3 on a scale of 100, and among a pool of 18 pharmaceutical companies, Novo Nordisk has climbed up from last year's ranking.